Patent: 9,199,999
✉ Email this page to a colleague
Summary for Patent: 9,199,999
| Title: | Substituted imidazopyrazines |
| Abstract: | The present invention relates to substituted imidazopyrazine compounds of general formula (I) in which A, R.sup.1, R.sup.3 and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. ##STR00001## |
| Inventor(s): | Klar; Ulrich (Berlin, DE), Koppitz; Marcus (Berlin, DE), Jautelat; Rolf (Haan, DE), Kosemund; Dirk (Berlin, DE), Bohlmann; Rolf (Berlin, DE), Bader; Benjamin (Berlin, DE), Lienau; Philip (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Scott; William (Guilford, CT) |
| Assignee: | Bayer Intellectual Property GmbH (Monheim, DE) |
| Application Number: | 13/700,956 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,199,999 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,199,999
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-06-01 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-06-01 |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2030-06-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
